UAMY Q2 Miss and Guidance Cut Trigger Sharp Sell-Off, but Balance Sheet Provides Buffer

What happened

United States Antimony reported second-quarter revenue of $7.9 million, below Wall Street expectations, and slashed its full-year revenue guidance from $125 million to a range of $60 million to $75 million, citing lower antimony prices and delays in government acceptance. The stock has plummeted this week as investors recalibrate to the sharply reduced outlook, which implies second-half revenue must more than triple the first half's $14.7 million just to hit the low end of guidance. However, the company's balance sheet remains a source of resilience, with $41 million in cash, $21 million in Treasuries, and a $43 million equity stake in Larvotto against only $9.6 million in total liabilities. The first two DLA shipments totaling about 82,000 pounds have been delivered, but revenue recognition slipped into Q3, leaving $2.6 million deferred and underscoring the execution risk around government acceptance timing. The market's focus now shifts to the third quarter, where management has guided to $9-10 million in additional U.S. government sales, which will be critical for validating the revised forecast and restoring confidence.

Implication

For current holders, the sell-off increases the attractiveness of the $5.25 entry point, but the WAIT rating remains appropriate until Q3 results confirm that shipment acceptance and margin expansion are on track. The revised guidance implies a steep ramp that carries meaningful execution risk; failure to achieve at least the guided $9-10 million in Q3 government revenue would likely pressure the stock further. Conversely, if Q3 shows strong conversion and gross margin improves above 15%, the stock could re-rate toward the $6.75 base-case value. Investors should monitor inventory levels, which at $21.6 million need to start drawing down, and any updates on Thompson Falls furnaces becoming fully operational. Given the binary nature of the next few quarters, position sizing should reflect the high uncertainty rather than a directional bet.

Thesis delta

The guidance cut and revenue miss were already incorporated into our WAIT rating, so the thesis is unchanged. The market's sharp sell-off may create a more attractive entry near $5.25, but it does not alter our fundamental view that the company must prove operational execution before the stock can sustainably rerate. We maintain our price targets and will reassess after Q3 results.